Center Laboratories reported a stellar 2025 fiscal year, with a net profit of NT$9.3 billion and an EPS of $12.33, the highest in seven years. Chairman Su-Ki Wong noted that the surge was fueled by the strong performance of Baoji Pharmaceuticals on the HKEX and a significant narrowing of equity-method investment losses.

Portfolio Highlights and 2026 Outlook:

• Jacobio Pharmaceuticals: Secured a global licensing deal with AstraZeneca for its Pan-KRAS inhibitor totaling up to US$2 billion.
• Baoji Pharmaceuticals: Its recombinant hyaluronidase (KJ017) is expected to receive China NMPA approval in H1 2026 for large-volume subcutaneous administration.
• EirGenix (Everest): Anticipates a recovery of up to NT$3.3 billion as CDMO giant WuXi Biologics takes a stake.

Center Labs remains optimistic for 2026, focusing capital on "Innovative R&D" and "Complex Manufacturing" (Difficult-to-Make) assets.

Resource: 晟德去年獲利逾一股本　EPS 12.33元寫7年新高、今年拚再寫紀錄